Alessandra Cesano Sells 12,150 Shares of Puma Biotechnology, Inc. (NASDAQ:PBYI) Stock

Puma Biotechnology, Inc. (NASDAQ:PBYI - Get Free Report) Director Alessandra Cesano sold 12,150 shares of the company's stock in a transaction on Friday, June 13th. The stock was sold at an average price of $3.40, for a total value of $41,310.00. Following the completion of the sale, the director now owns 68,850 shares of the company's stock, valued at $234,090. This represents a 15.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Puma Biotechnology Stock Down 0.6%

Shares of PBYI stock traded down $0.02 during mid-day trading on Tuesday, hitting $3.43. The stock had a trading volume of 210,811 shares, compared to its average volume of 443,805. Puma Biotechnology, Inc. has a 12-month low of $2.23 and a 12-month high of $4.13. The firm has a market capitalization of $170.23 million, a P/E ratio of 4.45 and a beta of 1.29. The firm's 50-day moving average is $3.20 and its two-hundred day moving average is $3.12. The company has a debt-to-equity ratio of 0.11, a current ratio of 1.53 and a quick ratio of 1.43.

Wall Street Analyst Weigh In

PBYI has been the subject of several research reports. HC Wainwright reiterated a "buy" rating and issued a $7.00 target price on shares of Puma Biotechnology in a report on Friday, February 28th. Wall Street Zen upgraded Puma Biotechnology from a "buy" rating to a "strong-buy" rating in a report on Thursday, May 22nd.

Institutional Investors Weigh In On Puma Biotechnology

Hedge funds have recently made changes to their positions in the stock. Wells Fargo & Company MN lifted its stake in shares of Puma Biotechnology by 36.5% during the 4th quarter. Wells Fargo & Company MN now owns 22,929 shares of the biopharmaceutical company's stock worth $70,000 after purchasing an additional 6,126 shares during the last quarter. Mackenzie Financial Corp purchased a new stake in shares of Puma Biotechnology during the 4th quarter worth $240,000. Bank of New York Mellon Corp lifted its stake in shares of Puma Biotechnology by 19.5% during the 4th quarter. Bank of New York Mellon Corp now owns 331,853 shares of the biopharmaceutical company's stock worth $1,012,000 after purchasing an additional 54,150 shares during the last quarter. American Century Companies Inc. lifted its stake in shares of Puma Biotechnology by 8.4% during the 4th quarter. American Century Companies Inc. now owns 948,376 shares of the biopharmaceutical company's stock worth $2,893,000 after purchasing an additional 73,833 shares during the last quarter. Finally, JPMorgan Chase & Co. lifted its stake in shares of Puma Biotechnology by 182.3% during the 4th quarter. JPMorgan Chase & Co. now owns 136,897 shares of the biopharmaceutical company's stock worth $418,000 after purchasing an additional 88,404 shares during the last quarter. 61.29% of the stock is currently owned by hedge funds and other institutional investors.

About Puma Biotechnology

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.